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Abstract There is increasing interest in making patient
participation an integral component of medical research.
However, practical guidance on optimizing this engage-
ment in healthcare is scarce. Since 2002, patient involve-
ment has been one of the key features of the Outcome
Measures in Rheumatology (OMERACT) international
consensus effort. Based on a review of cumulative data
from qualitative studies and internal surveys among
OMERACT participants, we explored the potential benefits
and challenges of involving patient research partners in
conferences and working group activities. We supple-
mented our review with personal experiences and
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reflections regarding patient participation in the OMER-
ACT process. We found that between 2002 and 2016, 67
patients have attended OMERACT conferences, of whom
28 had sustained involvement; many other patients con-
tributed to OMERACT working groups. Their participation
provided face validity to the OMERACT process and
expanded the research agenda. Essential facilitators have
been the financial commitment to guarantee sustainable
involvement of patients at these conferences, procedures
for recruitment, selection and support, and dedicated time
allocated in the program for patient issues. Current chal-
lenges include the representativeness of the patient panel,
risk of pseudo-professionalization, and disparity in
patients’ and researchers’ perception of involvement. In
conclusion, OMERACT has embedded long-term patient
involvement in the consensus-building process on the
measurement of core health outcomes. This integrative
process continues to evolve iteratively. We believe that the
practical points raised here can improve participatory
research implementation.
Key Points for Decision Makers
Outcome Measures in Rheumatology (OMERACT)
has shown that long-term involvement of patients in
research is beneficial for identifying and validating
outcomes that matter to patients.
Building and sustaining successful partnerships with
patients requires restructuring of the research process
and investing time and budgets into training and
support of patient research partners (PRPs).
The integration of qualitative and quantitative data,
complemented by participation of PRPs, enhances
the face validity of outcome research.
Ensuring representativeness of the patient
perspective for diagnosis, disease severity and
cultural, social-economic, and geographical diversity
is still challenging.
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1 Introduction
There is a growing trend in healthcare research to focus
more on outcomes that matter to patients, and more widely
on patient-centered research [1, 2]. To this end, the
involvement of patients not just as subjects of research but
as partners in the design, assessment, and implementation
of health research is recommended, and is sometimes
mandatory for grant approval [3–5]. In the USA, the
Patient-Centered Outcomes Research Institute (PCORI)
was established in 2010 to promote research that focuses
on those aspects of health that are most meaningful and
important to patients. PCORI involves patients at critical
stages of the research process to ensure that the questions
being asked are relevant and the results are meaningful to
people living with a given health condition [6]. In Canada,
a unique study explored perspectives of people with
osteoarthritis with full involvement of patients in all
research phases [7]. In the context of the Innovative
Medicine Initiative, the European Union, in collaboration
with the pharmaceutical industry, has initiated the Euro-
pean Patients’ Academy on Therapeutic Innovation
(EUPATI) to promote the education and active involve-
ment of patients in health research [8]. Internationally, the
Cochrane Collaboration involves patients in the develop-
ment of systematic reviews [9, 10]. The UK has the longest
tradition of public and patient involvement through a
National Institute of Health Research program called
Involve [11]. Within the specialty of rheumatology, the
European League Against Rheumatism (EULAR) [12],
Outcome Measures in Rheumatology (OMERACT), an
international consensus effort, and its member working
parties [13], the Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA) [14], and the
Assessment of SpondyloArthritis international Society
(ASAS) [15] have gained experience and published
regarding active involvement of patients in their main
activities. In the past years, EULAR and the American
College of Rheumatology (ACR) have included patient
representatives in their guideline development and other
initiatives. In several European countries, arthritis patient
organizations have established networks of trained research
partners [16, 17].
Although patient engagement in research is promoted, it
is often limited to evaluating research proposals for fund-
ing or participating in advocacy groups. However, patients
can contribute to research in different roles, not only as
respondents or study participants but also as advocates,
advisors, reviewers, or research partners (Fig. 1). When
referring to higher levels of engagement, involving close
collaboration in the research process itself, we use the term
‘patient research partner’ (PRP). A PRP is someone living
with the relevant disease or condition who participates as
an active team member on an equal basis with professional
researchers, adding the benefit of his/her experiential
knowledge to research projects [13]. There is limited
guidance on how high-level patient involvement in
research can be achieved, and few case studies to illustrate
its success [18–20].
OMERACT, an independent international organization
of health professionals, epidemiologists, outcomes
researchers, pharmaceutical representatives, and patients
[21], has engaged PRPs consistently and increasingly over
a period of 14 years [22]. The involvement of patients has
been rewarding for both the researchers and the patient
representatives. By collaborating with PRPs, relevant out-
comes for patients such as fatigue, well-being, and sleep-
disturbances have been identified, and PRPs have reported
increased knowledge, self-confidence, and empowerment
[23, 24]. OMERACT has incrementally learned how to
support, promote, and gain from this process. Here we
review how PRP involvement in OMERACT was devel-
oped, supported, and promoted, how challenges were
addressed, and the benefits that have accrued.
2 Outcome Measures in Rheumatology
(OMERACT) and the Involvement of Patients
The first OMERACT conference (1992) was convened at a
time of actively questioning traditional but arbitrary
approaches to assessing the benefits of treatment in rheu-
matic diseases. The conference aimed to consolidate
methodologically oriented approaches that had begun
separately in the USA through activities within the ACR
and in Europe through the World Health Organization and
International League of Associations of Rheumatology
(WHO/ILAR). One of the objectives of the first OMER-
ACT conference was to develop consensus on the mini-
mum number of outcome measures to be included in all
rheumatoid arthritis (RA) randomized controlled trials. The
conference brought together 92 rheumatologists,
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methodologists, regulatory officials, and pharmaceutical
industry researchers from around the world. Agreement
was achieved on the outcome domains that are known as
the RA core set [25].
Subsequent meetings of OMERACT followed every
2 years, developing and validating specific outcome mea-
sures and developing core sets for other rheumatic diseases
as proposed by Working Groups within OMERACT. The
basis of OMERACT is evidence-based discussions with
consensus through nominal group techniques.
In 2000, during discussions about ‘‘minimum clinically
important’’ differences in outcome measures [26], there
was uncertainty whether the perspective of physicians and
researchers was similar to that of patients. Concluding that
a representative consensus should include all three, the
final plenary voting session at the conference recognized
that the patients’ perspective was needed [27], and a
decision was made to invite patients to the next meeting.
The 11 PRPs who attended OMERACT 6 (2002) had a
limited degree of participation in the meeting. They were
asked to review the RA core set from the patient per-
spective and to identify domains that mattered to patients.
It became clear that the views of researchers and patients
were not identical [28]. Symptoms of importance to
patients such as fatigue, overall well-being, and sleep
disturbances were not included in the existing RA core set.
Also, the design of clinical trials at that time would not
provide patients with the information they felt was needed
to judge the success of new treatments. After this meeting,
the leadership of OMERACT and a sufficiently large pro-
portion of those actively involved in OMERACT-related
research were convinced that PRPs should continue to be
involved. Since then, between 17 and 21 patients have
participated in each of the OMERACT conferences
(Table 1).
Each meeting included patients with the rheumatologic
condition featured in the program because experiential
knowledge of the condition itself was felt to be critical.
Thirty of the 67 PRPs (45 %) have participated in at least
two OMERACT conferences, ten of whom have partici-
pated in at least four OMERACT conferences. In recent
years many more PRPs have been members of OMERACT
Working Groups, which carry forward the research agenda
between the biannual meetings.
The extent to which PRPs are integrated into the
OMERACT meeting program has steadily expanded
(Fig. 2). As a consequence, the timetable commitment for
PRPs during the meeting has increased from 7.5 h in 2002
to 47 h in 2016. In parallel, OMERACT has developed
systems for the selection and support of PRPs, with the
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Fig. 1 The empirical research circle: potential patient contributions
and potential patient roles in research. Phases of the empirical
research circle are in blue, examples of potential patient contributions
are in orange, and five potential patient roles in research are in black.
The role of patient research partner and patient advisor are applicable
throughout the research circle. The role of patient reviewer is
particularly relevant in the phase of assessing grant applications, often
used by research funding bodies. The roles of patient respondent or
patient participant mostly relate to the phase of data collection. The
role of patient advocate is generally beneficial in the phases of
fundraising, establishing supportive legislation for medical research,
and dissemination
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Table 1 Characteristics of patients attending Outcome Measures in Rheumatology (OMERACT) conferences
Characteristics 2002: Gold
Coast, QLD,
Australia
2004:
Asilomar,
CA, USA
2006: St.
Julian’s Bay,
Malta
2008:
Kanaskis,
AB, Canada
2010:
Borneo,
Malaysia
2012:
Pinehurst,
NC, USA
2014:
Budapest,
Hungary
2016:
Whistler,
BC, Canada
Sex
Female 9 13 12 11 10 15 18 18
Male 2 5 8 6 11 5 3 4
Previous attendance
Yes 0 6 15 8 14 10 16 14
No 11 12 5 9 7 10 5 8
Condition
Rheumatoid
arthritis
11 17 15 7 12 10 10 9
Osteoarthritis 1 1 1 1 2 1
Psoriatic arthritis 4 2 2 2 2 4
Fibromyalgia 3 1
Gout 3 2 2
Vasculitis 1 2 2 2 2
Ankylosing
spondylitis
2
Myositis 1 1 1
Polymyalgia
rheumatica
1 1 2
Connective tissue
diseases
1 1 1
Behc¸et’s syndrome 1 1
Chronic pain 1
Juvenile idiopathic
arthritis
1
Country
USA 1 2 3 6 4 7 6 7
UK 3 4 3 2 3 4 5 4
Australia 3 2 1 1 3 1
Norway 2 2 2 1
Sweden 1 2 3 1 1
Denmark 1 1
Canada 3 4 5 2 4 4 5
The Netherlands 1 2 2 1 4 3 4 4
Germany 1
New Zealand 1 1
France 1 1
Malaysia 3
Turkey 1
Italy 1
Proportion of all
attending the
conference (%)
7.9 7.0 7.4 9.0 18.1 10.2 9.5 10.0
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funding and organization of their attendance being a
practical challenge. However, developing and implement-
ing rules and guidelines recognizing that PRPs are an
essential element of all OMERACT activities has been the
greatest intellectual challenge [13].
3 Recognizing Patient Research Partners (PRPs)
as an Essential Element of all OMERACT
Activities
3.1 Endorsement by the Leadership and Full
Participation in the OMERACT Process
The continuous support of the OMERACT leadership has
been crucial, as has the continued increase of experience
and patient involvement (Fig. 2) [29]. Initiatives taken by
patients, such as producing the OMERACT Glossary
(which is now part of every conference information pack)
have gradually convinced the majority of OMERACT
participants that PRPs make a positive contribution.
Results from a recent survey of repeat OMERACT atten-
dees concluded that working with PRPs was one of the
aspects that made them return to these meetings [30].
OMERACT values the perspectives of all stakeholders
and stimulates open discussions through an interactive
meeting design. All participants should be treated as equals
and have the same opportunities to contribute to the pro-
cess. An introductory patient session familiarizes PRPs
with the conditions under discussion at the meeting,
OMERACT terminology, and procedures. Session moder-
ators provide patients with a pre-session subject overview
and provide an environment that encourages all stake-
holders, but particularly patients, to speak up and con-
tribute actively in all aspects of the meeting. When voting
on consensus decisions, PRPs have full voting rights. The
roles played by PRPs at and between OMERACT meetings
have steadily expanded to include leading, mentoring,
reporting small group discussions, chairing plenary
sessions, writing reports, helping to design and facilitate
research between meetings, securing funding, and writing
and editing papers.
3.2 Support of PRPs and the Sustainability
of Participation
OMERACT support for PRPs evolved as experience
working together accumulated. Increasing integration of
patients into the program (Fig. 2) combined with the
achievement of specific milestones was accompanied by
greater attention to the support of PRPs (Table 2). Orien-
tation and training sessions have been cumulative and
written into the conference program design. The increasing
time demand on PRPs has resulted in the introduction of
personalized programs to ensure that each PRP is able to
attend the sessions most relevant to their condition.
Arriving 1 day before the conference and scheduling
‘down time’ during the meeting are included to prevent
overburdening and respect disease management (e.g., time
for activities of daily living, resting, and doing exercises).
An important innovation in 2008 was the introduction of a
‘buddy system,’ where new patient participants are paired
with more experienced PRPs. New participants found this
extremely helpful [23].
Facilitating PRP participation in ongoing research
between meetings has been a challenge. Working Group
leaders have been confronted with practical issues such as
providing lay summaries of documents, preventing over-
burdening, ensuring sufficient lead time for PRPs to read
information and provide feedback, and adequate acknowl-
edgment of PRPs’ contributions. In addition, it is not always
clear whether (all) PRPs fulfil the criteria for authorship of
peer-reviewed publications. The criteria can vary between
groups, to some degree influenced by the PRP’s decision to
be coauthor or not. These processes are continually evolving.
3.3 Acceptance of the Role of PRPs by OMERACT
Members
In 2014, recommendations for the involvement of PRPs in
OMERACT Working Groups were approved by an over-
whelming majority at the OMERACT plenary voting ses-
sion [13]. Together with the appointment of a patient
delegate to the Executive Committee, this demonstrates the
OMERACT commitment to the principles and practice of
substantive patient engagement in the research process to
ensure the inclusion of that perspective as a mandatory
feature of high-quality outcomes research [13]. This point
was arrived at in a stepwise process, with many OMER-
ACT participants gradually changing their views on PRPs’
contributions, and realizing the value they can add to the
research process. These developments [29] can be
Fig. 2 Outcome measures in rheumatology (OMERACT) conference
timetabled hours designated for full participation of patient research
partners in the program and for patient research partners support
sessions
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summarized in the observation that increasing experience
of working with PRPs has the greatest influence on
researchers’ perceptions.
4 Organizing the Attendance of PRPs
4.1 Recruitment, Selection, and Representativeness
of PRPs
Potential OMERACT PRPs are first approached by a
member of a Working Group, usually a physician. Mini-
mum requirements include being diagnosed with the con-
dition being studied and the ability to speak English,
articulate the lived experience with the disease, and travel
abroad and participate in an intense 4-day OMERACT
working conference. The patient stream leader, who is one
of the members of the Executive Committee, approves
nominations and invites PRPs to attend the conference.
OMERACT aims at an adequate representation of conti-
nents, sexes, conditions, and experiences appropriate to
each conference program. Ensuring appropriate represen-
tativeness of PRPs has been an ongoing challenge. Detailed
characteristics have not been systematically collected, but
the majority of OMERACT PRPs have been white, middle-
class, middle-aged, and higher educated. Attempts have
been made to broaden the diversity of the OMERACT
PRPs, such as finding participants from Malaysia when the
meeting was held there, but it is difficult to involve patients
from countries where participatory research is less recog-
nized and physician–patient relationships are traditionally
more paternalistic [31]. Nevertheless, the countries of
residence of the PRPs (Table 1) are similar to those of the
rest of the participants in OMERACT, as is the proportion
Table 2 Milestones and cumulative patient research partner support activities: 2000–2016
Year Milestone PRP support activities
2000 Vote at the final plenary to include the patient perspective
at the next OMERACT
Establishment of Patient Stream Coordinator with allocated
funding for patient support
2002 First patients participating in the conference Participation in two main sessions only with special patient
group workshop
Pre-session briefing and post-session debriefing
Experienced clinical researcher available for questions,
discussion, and general support
Nominated clinician available for individual assistance
2004 Establishment of Patient Panel with a chair Production (by PRPs) of OMERACT Glossary
Post-meeting educational day in Bristol for European
patients
Patient newsletter started (by PRPs)
2006 First policy statement: patient involvement becomes
mandatory for module and workshop applications
Patients provided with their own meeting room
Brief patient introduction session before start of meeting
Patient Panel wrap-up meeting included in program
2008 PRPs responsible for supporting each other Substantial patient introduction session before start of
meeting
Buddy system introduced
Pre-conference PRP dinner
OMERACT Glossary in conference information pack for
all attendees
Fatigue included as a recommended outcome in the RA
core set
2010 Second policy statement: integral involvement of patients
in all working groups
Daily patient update sessions introduced
2012 Evaluation of a decade of patient involvement in
OMERACT presented
Pre-conference patient information pack, including lay
summaries of all the sessions
Introduction of personalized programs
PRPs fully involved in development of OMERACT Filter
2.0
2014 Consensus on recommendations for the involvement of
patient research partners in OMERACT working groups
approved
Daily patient evaluation sessions introduced
PRP becomes a member of OMERACT Executive
2016 Preparatory internet seminars for patients
OMERACT Outcome Measures in Rheumatology, PRP patient research partner
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residing in the USA, Europe, and elsewhere (23, 48, and
29 %, respectively, for PRPs compared with 30, 45, and
25 % for other participants).
Patients and their treating physician are often both
involved in OMERACT research, requiring a separation of
roles of patient/doctor in the clinic from that of collabo-
rative partners at OMERACT [32]. To facilitate this, each
OMERACT meeting has a designated consultant physician
available for patients if they have health concerns.
OMERACT expects PRPs to represent their personal
perspective of living with the disease, not that of a par-
ticular group of patients. Guidelines have been developed
to help PRPs and researchers focus on the personal lived
experience rather than personal agendas or organizational
advocacy [13].
4.2 Resources for Participation
Patient participation in research, and in particular at con-
ferences, requires financial resources. The cost of each PRP
attending OMERACT have been met by OMERACT funds
or donations organized by Working Groups. These
expenses have been considerable, and accommodating
patients with severe disabilities may require special trans-
portation arrangements (e.g., supplemental oxygen on
flights, personal assistance, or special travel arrangements).
The average cost per patient has been similar for almost all
meetings; the total cost for patient attendance for each of
the last three meetings has been approximately
US$100,000 per meeting (in 2014 values [US$] after cor-
rection for US inflation). This is a considerable portion of
the central funds available to OMERACT and represents a
major fundraising commitment by the OMERACT Exec-
utive Committee.
5 Challenges and Benefits
5.1 Demonstrating the Impact of PRPs
There is evidence that engaging patients structurally in
outcomes research provides benefits for the overall
research process [5, 33, 34]. Patients’ questions, opinions,
and concerns provided face validity to the OMERACT
process and widened the research agenda [24]. New
domains, including fatigue, foot problems, stiffness defi-
nition, work productivity, and flares, were identified by
patients and prompted new research. The involvement of
PRPs enhanced the inclusion of patient-relevant outcomes
in core sets. It changed the culture of OMERACT and may
influence practice in other disciplines and research con-
texts. At the individual level, PRPs reported ‘positive pay-
back’ in feeling more empowered towards their own
disease, they appreciated opportunities to contribute to the
greater community, and felt better able to keep abreast of
research developments related to their disease [24].
In the 2014 OMERACT survey, Working Group leaders
valued the PRPs’ feedback as a reality check of the rele-
vance and quality of their project, and stated that the
feedback influenced the choice of appropriate outcomes
and instruments. Interestingly, patients were less certain
about the added value of their experiential knowledge to
the overall research. This confirms earlier findings that
patients tend to underestimate their contribution to the
research process [23].
5.2 Risk of Pseudo-Professionalization
Almost half of OMERACT PRPs have attended two or
more OMERACT conferences and some are highly
involved in other ongoing research projects. As these
patient participants have become more experienced, some
researchers have welcomed their increased familiarity with
research processes and vocabulary. However, others have
questioned the authenticity of their patient perspective
because they felt training and support over a long period of
time could result in ‘professional patients’ who are not able
to represent the ‘naı¨ve’ or ‘authentic’ patient perspective
[29] and therefore do not represent ‘ordinary’ patients.
Whether this is true is open to debate [29], but OMERACT
minimizes this risk by ensuring a mixture of new and more
experienced PRPs at meetings, and by focusing education
on the ability of PRPs to articulate their personal experi-
ence in the context of outcome research.
5.3 Extent of Patient Participation Between
Meetings
A 2014 internal OMERACT survey showed that 14 of 18
Working Group leaders reported patient involvement
between conferences, usually including at least two PRPs.
Involvement included regular electronic communications,
teleconferences, and face-to-face meetings where possible.
The survey revealed differences between researchers and
PRPs in their perception of the role played by PRPs. Most
PRPs perceived themselves as ‘‘advisors’’ or ‘‘information
providers’’; four viewed themselves as collaborators and
one PRP reported a leadership role. In contrast, Working
Group leaders perceived that PRPs had higher levels of
involvement: ten Working Group leaders viewed PRPs as
‘‘collaborators’’ in their projects and two Working Group
leaders mentioned the role as being ‘‘in control’’. This
disparity might be explained by the varying maturity of
Working Groups in regards to their activities and the ten-
dency of PRPs to underestimate the influence of their
participation [23].
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5.4 PRPs in Different Types of Projects
There remains some debate as to whether the appropriate
extent of patient participation may depend on the particular
research project. Although OMERACT recommends
involvement of patients as PRPs throughout the research
process, in reality this is not always feasible. Some patients
provide valuable input into one or more research phases,
not as a PRP but as a patient advisor. For example, in a
study to develop or evaluate a new imaging modality, it
may be argued that patients’ perspectives are not as nec-
essary for the assessment of the measurement algorithms or
scoring method. However, it would be appropriate for
patients to comment on the burden, safety, and feasibility
of a test and to understand how the results could be used in
guiding their care.
5.5 Examples of PRPs in Working Groups
A detailed analysis of the consequences of PRP involve-
ment in OMERACT has been published [24, 27]. Here we
showcase two working groups that substantively engaged
patients in all their activities. After patients identified
fatigue as an often ignored and under-researched disease
symptom, the OMERACT Fatigue Working Group initi-
ated a research agenda with studies at different centers to
systematically explore the phenomenon of fatigue. The
Working Group looked at its severity and evaluated
existing measurement instruments and are developing new
ones. Patients have been involved on different levels and in
different roles [35]. In the development of a new patient-
reported outcome measure for fatigue, patients played a
pivotal role in focus group meetings, individual interviews,
surveys, clinical trials, cognitive interviews, as well as in
the OMERACT Working Group. The result has been a new
instrument, the Bristol Rheumatoid Arthritis Fatigue
(BRAF) questionnaire [36], which is based on the con-
ceptual framework developed from qualitative studies,
ensuring its face validity. New data on the impact and
measurement of fatigue have resulted in the recommen-
dation to measure fatigue in clinical trials [37] and in
clinical care to reconcile disparities between physician and
patient assessments of disease activity [38].
The OMERACT RA Flare Working Group involved
patients from its initiation through every stage of the pro-
ject. Since the inception of the project in 2006, the role of
PRPs has been intense and diverse [35]. Tasks were related
to developing the design of the study, co-organizing focus
group meetings, and coding and analyzing transcripts.
PRPs participated in international, bi-weekly teleconfer-
ences to discuss the development of an instrument to
measure flares, and a patient committee held additional
face-to-face meetings and teleconferences with other group
leaders for feedback and discussion of research progress
and interim findings [39]. This work is ongoing.
6 Discussion
The way patients are involved as research partners in
OMERACT has grown from an initial tightly circum-
scribed and experimental arrangement in 2002 to complete
involvement at all levels of activity, supported by an
inclusive and supportive code of practice approved by the
membership in 2014. During this time, OMERACT has
successfully introduced a number of conceptual, structural,
and practical processes to ensure the integration of the
patient perspective and substantive engagement throughout
outcome measure development. These have centered on
recognizing PRPs as an essential element of all OMER-
ACT activities and funding and organizing the attendance
of PRPs. Initial leadership commitment to providing
resources for participation and a structure for the recruit-
ment, selection, and support of PRPs was crucial. The
experience of working with PRPs led to a stepwise
acceptance and then encouragement of the role by
OMERACT members and has resulted in increased PRP
engagement in Working Group activities between
OMERACT meetings. This approach can be applied by
other societies and research groups [40], and may result in
the development of different structural and procedural
changes to ensure that PRPs are supported and productive
in that setting.
PRP inclusion in the OMERACT process is not intended
to represent the perspective of all patients as they only
represent themselves and their experiences. However,
having two patients within a Working Group, whatever
their background and experience, is infinitely better than
not involving patients at all. Ensuring a more representa-
tive view may be achieved through the use of mixed
research methods that include qualitative interviews, focus
groups, Delphi methods, or surveys to expand the input
across a wider spectrum of patients [19]. Such methods are
increasingly recognized as an essential requisite of out-
comes research in identifying and defining the concept of
measurement (e.g., what you are seeking to measure)
grounded in the patient experience, and to ensure that the
ultimate measure is reflective of this concept [2].
While many have advocated increased participation in
research, developing metrics to demonstrate the added
value of such inclusion is challenging. In this report we
provide not only experiential evidence from the perspec-
tives of patients and researchers, but real evidence of
change in the direction of research endeavors, and more
detailed analyses are available [17, 23, 24, 27, 29, 30]. The
recognition of fatigue as an important aspect of living with
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RA has now been incorporated into recommendations for
patient assessments in clinical care, and for clinical trials,
though the optimal measure has yet to be defined. There are
few publications that have described methods of successful
engagement in detail [41], and further studies are needed to
provide additional evidence of the benefits and impact of
patient participation.
While the work reported here has been limited to
rheumatology, the conceptual foundations and the
framework developed for patient inclusion are widely
applicable across all chronic diseases and beyond out-
comes research [42, 43]. EULAR now recommends
involvement of PRPs throughout the research process,
preferably from the beginning [12]. PCORI has also
recently developed a rubric for patient and stakeholder
engagement that provides examples of how patients can
be involved at different phases of research [44, 45]. The
US Food & Drug Administration Critical Path Initiative,
the Core Outcome Measures in Effectiveness Trials
(COMET) initiative [46], and the International Society for
Quality of Life research (ISOQOL) [47] have also begun
to integrate PRPs in their work. The process explained
here should be useful in other contexts and to other
specialties. Moving such an agenda forward is time con-
suming and necessitates enthusiasm and perseverance,
particularly to support and train patients and health pro-
fessionals. However, OMERACT researchers value
patient participation highly in conferences and this is one
of the central reasons for their ongoing participation [30].
The dialogue and engagement between researchers and
PRPs has greatly improved the quality of core outcome
sets, by ensuring that outcomes are relevant to patients
[48, 49]. Patient participation has enriched the research
agendas and enhanced mutual understanding of outcomes
of importance for both patients and researchers [24].
The experience of OMERACT should help move policy
makers, funders, and researchers closer to the view that
participatory research is not only a normative imperative
for outcome research, but is also effective in producing
relevant research and health outcomes [41].
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